Harrow announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora, a pharmaceutical solutions organization that provides comprehensive solutions to facilitate and optimize market access to therapies. Its services range from real-time benefit verifications to flexible affordability options and product assurance programs.
Harrow Cares delivers a comprehensive suite of high quality access and affordability services, enhancing support for retina specialists, their staff and patients, Harrow said in a press release. Through a patient support services hub, Harrow Cares ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize Iheezo and Triesence in their practices, the company said.
Key features of the Harrow Cares program include:
- Streamlined enrollment: Providers can enroll via multiple channels, including phone, a dedicated provider portal or PXConnect technology integration.
- Rapid access to therapy: Services provide real-time benefit verifications, enabling retina specialists to quickly verify patient benefits and secure timely access to treatment.
- Flexible affordability: Includes an in-house commercial copay assistance program, patient assistance options, and referrals to third-party charitable foundations, allowing patients to pay as little as $0.
- Assurance and ongoing support: Additional features include patient-welcome calls, annual reverification support, escalation for prior authorization denials and assurance through product replacement programs.
“We are thrilled to collaborate with Cencora on the launch of our ‘Harrow Cares’ program,” said Mark L. Baum, CEO of Harrow, in the press release. “This partnership reflects our shared commitment to addressing one of the most critical challenges in health care—ensuring that life changing medications are both accessible and affordable. The Harrow Cares initiative underscores Harrow’s unwavering dedication to creating meaningful solutions that empower patients, reduce barriers to treatment, and drive better health outcomes. Furthermore, this milestone highlights our strategic focus on expanding and solidifying Harrow’s presence in the US retina market, a key area of growth and innovation for our company. We look forward to working closely with Cencora to advance innovative ophthalmic solutions that enhance patient care and improve access to vital treatments.”